Why Is AstraZeneca Stock Trading Lower On Tuesday?
Why Is AstraZeneca Stock Trading Lower On Tuesday?
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial.
阿斯利康公司（纳斯达克股票代码：AZN）周二表示，在Tropion-Lung01三期试验的总试验人群中，存活结果未达到统计学意义。
Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated with at least one prior line of therapy.
Tropion-Lung01 3期试验的最高总存活率（OS）结果，该试验之前达到了无进展存活率（PFS）的双重主要终点，与多西他赛相比，在接受过至少一种先前疗法治疗的局部晚期或转移性非小细胞肺癌（NSCLC）患者中，与多西他赛相比，在数字上更受青睐。
Also Read: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion.
另请阅读： 阿斯利康的目标是通过管道扩张，到2030年实现800亿美元的总收入。
In the pre-specified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful improvement in OS compared to docetaxel, the current standard of care chemotherapy.
在预先指定的非鳞状非小细胞肺癌患者亚组中，与目前的护理化疗标准多西他赛相比，datopotamab deruxtecan显示出具有临床意义的改善。
Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) and being jointly developed by Daiichi Sankyo and AstraZeneca.
Datopotamab deruxtecan 是由第一三共公司（OTC: DSKYF）（场外交易代码：DSKYF）（场外交易代码：DSNKY）发现的一种专门设计的 TROP2 导向 dxD 抗体药物偶联物，由第一三共和阿斯利康共同开发。
The final analysis of OS builds on the PFS results presented at the European Society for Medical Oncology 2023 Congress, which showed that datopotamab deruxtecan demonstrated a statistically significant improvement in PFS in the overall trial population and a clinically meaningful PFS benefit in patients with nonsquamous NSCLC.
操作系统的最终分析建立在欧洲肿瘤内科学会2023年大会上公布的PFS结果基础上，该结果显示，达托泊他单德鲁替康在整个试验人群中显示出具有统计学意义的显著改善，非鳞状非小细胞肺癌患者的PFS益处具有临床意义。
The safety profile of datopotamab deruxtecan in TROPION-Lung01 was consistent with the previous analysis, including fewer dose reductions or discontinuations due to adverse events compared to docetaxel and with no new safety concerns identified. No new interstitial lung disease events of any grade were adjudicated as drug-related.
Datopotamab deruxtecan在Tropion-Lung01中的安全性概况与先前的分析一致，包括与多西他赛相比，由于不良事件导致的剂量减少或停药较少，也没有发现新的安全问题。没有任何级别的新间质性肺病事件被裁定为与药物有关。
"Datopotamab deruxtecan is the only investigational therapy to show a clinically meaningful survival improvement in patients with previously treated nonsquamous non-small cell lung cancer versus docetaxel, which has long been unsurpassed in this post-targeted treatment and post-immunotherapy setting," said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca.
阿斯利康肿瘤学研发执行副总裁苏珊·加尔布雷思说：“与多西他赛相比，Datopotamab deruxtecan是唯一一种显示先前接受过治疗的非鳞状非小细胞肺癌患者存活率有临床意义改善的在研疗法，多西他赛在这种靶向后治疗和免疫后治疗环境中一直是无与伦比的。”
TROPION-Lung01 enrolled approximately 600 patients.
Tropion-Lung01 招收了大约 600 名患者。
Price Action: AZN shares were down 2.40% at $76.66 at the last check on Tuesday.
价格走势：在周二的最后一次支票中，AZN股价下跌2.40％，至76.66美元。
Image by Robert Way via Shutterstock
图片由 Robert Way 通过 Shutterstock 提供